Radioresistance in prospectively Isolated Cancer Stem Cells in Esophageal Cancer Patients: RARESTEM-Organoid Study

Radioresistance in prospectively Isolated Cancer Stem Cells in Esophageal Cancer Patients: RARESTEM-Organoid Study - RARESTEM Organoid Study

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

NL-OMON

Registry ID

NL-OMON45161

Enrollment

200

Registered

2009-11-05

Start date

2009-12-11

Completion date

Unknown

Last updated

2024-05-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

predictie respons (chemo/radiotherapie in relatie tot kankerstamcelonderzoek (CSC) op basis van tumor gerelateerde organoids Cancerstemcell analyses in patients tumor derived organoids: assessing response of chemoradiotherapy in esophageal cancer

Interventions

None listed

Eligibility

Age

18 Years to 99 Years

Inclusion criteria

Inclusion criteria: All patients in whom a curative intended treatment/ esophageal resection can be performed. All patient who underwent a endoscopic ultrasound (EUS) procedure for staging and had given permission for additional biopsies of the tumor and normal esophageal mucosa. Patients should participate in the standard protocol for neo-adjuvant or definitive chemoradiotherapy

Exclusion criteria

Exclusion criteria: Patients who are medically unfit for a curative treatment Patients who are mentally disabled or incapable to give informed consent Patients with distant disease Patients with other intercurrent malignancies except in- situ ca.

Design outcomes

Primary

Measure	Time frame
Question 1: Radioresistance; the effective dose 50% (ED50%) of CSCs enriched subpopulation will be compared with the ED50% esophageal cancer cell lines (control group). Question 2: The percentage of CSCs will be analysed for a possible correlation between for survival, disease-free survival and recurrences (yes vs no).	—

Countries

Netherlands

Outcome results